Stock Quote

ACOR (Common Stock) $ 39.66 +0.52 (+1.33%) Volume: 266,076 MORE December 26, 2014

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *






Corporate Governance

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS and spinal cord injury.

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

Chairperson Member Financial Expert
  Audit Commitee Compensation Commitee Compliance Commitee Nominations & Governance Commitee
Barry Greene
Peder Jensen
John Kelley
Sandra Panem, Ph.D.
Lorin J. Randall
Steven M. Rauscher
Ian F. Smith